Mineralys Therapeutics (MLYS) Cash & Equivalents (2022 - 2026)

Mineralys Therapeutics has reported Cash & Equivalents for 5 years, with the latest figure at $111.6 million in Q1 2026.

• Quarterly Cash & Equivalents fell 32.35% year-over-year to $111.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $111.6 million (down 32.35% YoY) and the FY2025 annual result came in at $172.9 million, up 51.56% from the prior year.
• Cash & Equivalents eased to $111.6 million in Q1 2026 per MLYS's latest filing, from $172.9 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $217.6 million in Q3 2025 and troughed at $49.3 million in Q4 2023.
• A 5-year average of $113.4 million and a median of $99.0 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents slumped 43.78% in 2023, then soared 131.4% in 2024.
• Over 5 years, Cash & Equivalents stood at $87.7 million in 2022, then plunged by 43.78% to $49.3 million in 2023, then jumped by 131.4% to $114.1 million in 2024, then jumped by 51.56% to $172.9 million in 2025, then plunged by 35.45% to $111.6 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $111.6 million, $172.9 million, and $217.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.